Clinical trial · Observational
Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers
Non Randomized Parallel-group Clinical Study to Compare the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Comparing the structural effects of TNFi and tocilizumab on the periarticular bone by performing a comprehensive analysis of the periarticular bone changes in RA patients treated with either TNFi or tocilizumab in a longitudinal Setting, using high-resolution peripheral quantitative computed tomography (HR-pQCT), a very sensitive method for visualizing and quantifying bone microstructure in RA patients. Quantitatively assessing the changes of erosions volume, osteophytes size and the area of cortical fenestration in a group of TNFi-treated and a group of tocilizumab- treated RA patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Rheumatoid Arthritis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| TNF-alpha Inhibitor | Drug | — | UNRESOLVED |
| Tocilizumab | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Tocilizumab
- description
- Drug administration of Tocilizumab s.c. or i.v. depending on the preference of the patient and/or physician according to the label
- interventionNames
- Drug: Tocilizumab
- Drug: TNF-alpha Inhibitor
- label
- TNF-alpha Inhibitor
- description
- Drug administration s.c. or i.v. of the TNF-Alpha Inhibitor depending on the preference of the patient and/or physician according to the label
- interventionNames
- Drug: Tocilizumab
- Drug: TNF-alpha Inhibitor
Primary outcomes (1)
- measure
- Change in erosion volume in the HR-pQCT
- timeFrame
- 12 months
Secondary outcomes (6)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Females and males with RA erosions in the wrist and/or MCP joints * Must be aged ≥ 18 years at time of consent * Stable treatment with conventional DMARDs of at least 3 months Exclusion Criteria: * Patients exposed to abatacept or rituximab in the last 12 months * Patients receiving glucocorticoids over 5 mg prednisolone per day * Patients who are younger than 18 years * Pregnant or lactating females * Patients having received an HR-pQCT examination during the last 6 months before screening
References
Publications (0)
Data not yet available